Objective: To investigate the mode of action of methotrexate (MTX) in different types of models for rheumatoid arthritis (RA) and multiple sclerosis (MS). Methods: Models for RA and MS were selected known to have different pathogenesis-that is, fibroblast induced arthritis in SCID mice, collagen induced arthritis (CIA), anticollagen II antibody induced arthritis (CAIA), and experimental autoimmune encephalomyelitis (EAE) in (Balb/c6B10.Q)F1 and B10.Q mice, and Pristane induced arthritis in DA rats (PIA). The MTX treatment was started 1 day after the onset of disease and continued for 14 days to compare effects on the different models.
S
everal disease modifying antirheumatic drugs (DMARDs) are used in the treatment of rheumatoid arthritis (RA). The two most important DMARDs today are inhibitors of tumour necrosis factor a (TNFa) and methotrexate (MTX). 1 MTX is an analogue of folic acid and is an anti-metabolite and a potent inhibitor of dihydrofolate reductase, which subsequently inhibits the de novo purine and pyrimidine synthesis. Based on these properties it was developed as a cytostatic agent. Several pharmacological mechanisms for MTX have been reported. It has been shown to act through various mechanisms such as direct promotion of synovial cell apoptosis, thereby reducing pannus formation, 2 blocking proliferation of lymphocytes, 3 inhibiting interleukin 1 production 4 and vascular endothelial cell proliferation, 5 and increasing adenosine release. 6 The arthritis suppressive effect of low dose MTX treatment used today has not been clarified, although cytokine patterns are disturbed, and it is unclear whether the disease promoting mechanism also involves immune priming or only effector functions of the inflammatory attack. Differences in MTX response would depend not only on the state of the disease progress in the patient with RA but also on the type of molecular pathway involved, as RA is probably a heterogeneous syndrome rather than a specific disease entity.
To investigate the effects of MTX on experimental models of RA we used four different models that represent various facets of RA: the well known collagen induced arthritis model (CIA) in mice, 7 the anticollagen II (CII) antibody induced arthritis (CAIA) in mice, 8 the Pristane induced arthritis model (PIA) in rats, 9 and the new fibroblast induced arthritis model (LS48-SCID) in mice. 10 To compare the effects of these disease models we initiated treatment 1 day after the onset of disease and continued the treatment for 14 days.
METHODS

Animals
The animals for the CIA, CAIA, PIA, and experimental autoimmune encephalomyelitis (EAE) experiments were bred and kept at the animal department of medical inflammation research, which is a conventional department with a climate controlled environment with 12 hours light/ dark cycles and water and food given freely. For the CIA and CAIA experiments we used (C57/BL10.Q6Balb/c)F1 mice (termed QB). For the EAE experiments we used C57Bl/10.Q mice (termed BQ) and for the PIA experiments we used DA rats. The LS48 induced arthritis was performed in the Medizinisch-Experimentelles-Zentrum of the university of Leipzig (Germany) under specific pathogen-free conditions (27˚C, 80% air humidity, 12 hours light/dark cycles) and with water and food given freely. The mice were female C.B-17-SCID/IcrCrl mice purchased from Charles River (Wiga, Sulzfeld, Germany) and acclimatised for at least 1 week before any experimental manipulation and kept in laminar flow filter cabinets.
All animals used were matched for age and sex and the animals were marked, randomly mixed in the cages, and scored by investigators in a blinded fashion. Animal experiments followed national guidelines for animal experiments and were approved by the local animal protection committees in Sweden and Germany, respectively.
Methotrexate (MTX) treatment MTX was purchased from Medac (Hamburg, Germany) and diluted in phosphate buffered saline (PBS) in accordance with the weight of the animals and the concentration required for the experiment. It was kept in the dark at 4˚C. Animals were treated by daily intraperitoneal (IP) injections of indicated concentrations of MTX in PBS, in mice using a volume of 200 ml and in rats 1 ml for each injection. Identical treatment with PBS only was used as a control. The highest doses (5 mg/kg in the mouse and 0.1 mg/kg in the rat) used were identified through a dose titration experiment in which higher doses gave toxic effects as indicated by fever, drowsiness, and mortality. From this maximal dose a dose titration was performed. The actual highest dose used in the rat was still slightly toxic in the experiment performed.
CIA CIA was induced using native rat CII prepared from a rat chondrosarcoma after pepsin digestion as previously described. 11 The CII was emulsified in complete Freund's adjuvant (CFA, Difco, Detroit, MI) to a final concentration of 1 mg/ml, and 100 ml was injected intradermally at the base of the tail of QB mice on day 0. The mice were boosted on day 21 with a 50 ml injection intradermally at the base of the tail with a homogenate containing 50 mg CII suspended in incomplete Freund's adjuvant (Difco), prepared as described above. Clinical scoring was performed as described earlier. 11 Briefly, each inflamed toe or knuckle gives one point, whereas an inflamed wrist or ankle gives five points, resulting in a maximal score of 15 (five toes + five knuckles + one wrist/ankle) for each paw and 60 points for each mouse. All mice were scored daily. One day after onset of the disease (score >1 point) the treatment was started. Arthritic mice received PBS or MTX daily by IP injection (200 ml) for 14 days. The animals were killed on the last day of the treatment. The mice were bled on day 0, day 21, and then individually on days 7, 10, and 14 after disease onset. The levels of anti-CII IgG were determined by a quantitative enzyme linked immunosorbent assay (ELISA) as described earlier. 11 For the induction of CAIA we used purified CIIspecific monoclonal antibodies M2139 (IgG2b) and CIIC1 (IgG2a). Male mice, at least 16 weeks old, were injected intravenously with a combination of the two monoclonal antibodies(M2139 and CIIC1) at a total concentration of 9 mg for each mouse. Control mice received an equivalent volume of PBS. On day 5, all mice were injected IP with lipopolysaccharide (50 mg/mouse). The scoring and treatment were performed as described above.
PIA
For the PIA experiment we used male and female rats aged between 8 and 10 weeks, which were immunised intradermally at the base of the tail with 150 ml Pristane (Sigma).
LS48 induced arthritis
The LS48 cell line (German collection of micro-organisms and cell cultures, Braunschweig (DSMZ) accession number DSM ACC 2455; Biotectid, Leipzig, Germany) is a permanently growing murine cell line with characteristics of fibroblasts and without the tendency to express subclones. Cells were cultured using 75 cm 3 culture flasks (Greiner, Solingen, Germany) with 1610 5 cells/ml in a cell culture medium containing Dulbecco's modified Eagle's medium and RPMI 1640 (1:2), 10% fetal calf serum, 25 mM HEPES, penicillin (100 U/ml), and streptomycin (100 mg/ml; all Gibco, Eggenstein, Germany; hereafter called the culture medium). At confluency, the cells were trypsinised with trypsin-EDTA (0.25% trypsin/0.2% EDTA; Gibco) for 5 minutes and diluted 1:2 in 150 cm 3 culture flasks. To induce arthritis the mice were anaesthesised by an IP application of a combination of metomidate (6 mg/100 g body weight) and fentanyl (0.006 mg/100 g body weight); the injection site was shaved and disinfected. Cells (5610 5 ) suspended in 20 ml PBS were instilled into the right knee joints through the patellar tendon.
Joint swelling (both the injected and non-injected side) was monitored daily by measuring the diameter with caliper. Treatment was performed as described above starting 1 day after injection of the cells and continuing for 14 days. The mice were killed on the last day of the treatment. To prepare serial paraffin sections, the knee joints were fixed in 4% paraformaldehyde for 2 days, then placed in a decalcifying solution (70 ml of 85% formic acid, 85 ml of 30% hydrochloric acid, 70 g AlCl 3 , 1 litre of distilled water) for 24 hours. The joints were transferred into a graded series of ethanol (70%, 80%, 96%, 100%) for several hours and placed subsequently in methyl benzoate (10 hours), xylene (3 hours), and paraffin (20 hours) before they were embedded in paraffin blocks. The extent of joint destruction was assessed histologically by evaluating haematoxylin/eosin stained paraffin sections (5-7 mm). All histology reagents were obtained from Merck.
EAE EAE was induced using 150 mg synthetic MOG 79-90 peptide, emulsified in Mycobacterium tuberculosis H37Ra in CFA (Difco, Detroit, MI; equal volume of peptide/PBS and CFA). This solution was homogenised, and 100 ml of the homogenate was injected intradermally at the base of the tail. Pertussis toxin (500 ng) was given IP immediately after and 48 hours after immunisation. All animals were weighed and scored daily. Clinical score was designated as follows: 0, no detectable signs of EAE; 1, affected tail tonus; 2, tail paralysis: 3, mild hind leg paresis; 4, severe hind leg paresis; 5, one hind leg paralysis; 6, complete hind leg paralysis; 7, complete hind leg paralysis and fore legs paresis; 8, death as described earlier. 12 At a score of 5 or more, the mice got 0.5-1.0 ml 0.1% NaCl subcutaneously in the neck. Affected mice received PBS or well defined amounts of MTX daily by IP injection (200 ml) for 14 days. The animals were killed individually on the last day of the treatment. Figure 2 MTX treatment of CAIA. One group of mice were treated with MTX (2.5 mg/kg; n = 13) and a control group were treated with PBS (n = 13) starting 1 day after the onset of arthritis. Control mice were treated with PBS only. The mean score of all mice for each day is given with the SEM. No significant effect of MTX was seen.
Statistics
All comparisons of disease scores include all animals in the experiment, and the statistical analysis was carried out using the software Statview. A non-parametric Mann-Whitney test was used when two groups were compared or a KruskalWallis test for more than two groups. A p value of ,0.05 was regarded as significant.
RESULTS
Dose titration and treatment of CIA To determine the most effective dose of MTX we first performed a dose titration study on CIA. The mice showed the first signs of arthritis around day 21 after immunisation and thereafter each mouse with arthritis was randomly selected to be treated with different doses of MTX (0.1 mg/ kg; 2.5 mg/kg; 5 mg/kg) or PBS. The MTX treatment had a significant and dose dependent effect on the score of the disease (fig1), with maximal effect for the intermediate dose of 2.5 mg/kg. No toxic effects were seen at any of the doses used. All the mice developed a high anti-CII antibody titre independent of the arthritis severity and the MTX dose ( fig 1B) .
CAIA
For the treatment of the CAIA model we selected the most efficient MTX dose (2.5 mg/kg) and the treatment was Figure 3 MTX treatment of PIA. Day 0 indicates onset of arthritis of each rat, and MTX was given at different doses starting 1 day after the onset. The rats were treated with 0.05 mg MTX/kg (n = 6), 0.075 mg MTX/kg (n = 6), 0.1 mg MTX/kg (n = 13), and a control group were treated with PBS (n = 6). The mean score of all rats for each day is given with the SEM. *Indicates significant differences in severity scores, p,0.05, for all MTX treated groups in comparison with the control group. In the group with highest MTX dose (0.1 mg MTX/kg) eight rats died at different times during the experiment. Figure 4 MTX treatment of fibroblast induced arthritis in SCID mice. MTX was given at different doses (5 mg/kg, 2.5 mg/kg, 0.1 mg/kg) and PBS was given in the control group (n = 9 in each group) starting 1 day after the injection of the fibroblasts, when all mice had already developed arthritis. Scoring started at day 1 when the arthritis began and treatment was given from this day and then daily until day 14. The mean diameter of the injected left knee of all mice in each group for each day is given with the SEM. No significant effect of MTX was seen.
started after the onset of arthritis, which was around 5 days after the monoclonal anti-CII antibody injection. All mice continued the expected development of arthritis as seen in this model but with no effect of MTX treatment (fig 2) .
PIA
All animals developed a severe PIA with a sudden onset around day 12 after immunisation ( fig 3) . The doses we used for the mice were found to be toxic for the rats in a previous pilot experiment (data not shown). We therefore predetermined a series of lower doses that showed no toxicity. Thus the doses used in the experiment shown in fig 3 were 0. 1 mg/ kg, 0.075 mg/kg, and 0.05 mg/kg. All doses of MTX used had a significant ameliorative effect on the arthritis but with no obvious dose-titration effect. Possibly, the effect seen was maximal as the joint in this model rapidly gets destroyed and the healing process is difficult to distinguish from the inflammatory process.
LS48 induced arthritis
To bypass both antibody and T cell mediated pathways in the development of arthritis we used a previously undescribed model which is induced by injection of a fibroblast cell line (LS48) into an SCID mouse. Arthritis developed as expected, starting at day 1, and was recorded by measuring the thickness of the knee joints every day (fig 4) . The mice were treated with the same doses as used for the CIA experiment (0.1 mg/kg; 2.5 mg/kg, and 5 mg/kg MTX or PBS) starting after the onset of arthritis. To confirm the development of arthritis, histology sections were made at the end of the experiment (day 14; fig 5) . Surprisingly, we could not see any effect of the MTX treatment.
EAE
To determine the effect of MTX on another inflammatory disease with a clearly documented T cell dependent pathway we selected an EAE model. The mice developed the first signs of the disease 10 days after MOG peptide injection and as with the arthritis model we started the treatment the first day after onset in each mouse (fig 6) . The mice were treated with the same doses of MTX as used in the CIA experiment (0.1 mg/kg; 2.5 mg/kg; 5 mg/kg) or PBS. The treatment had a significant and dose dependent effect on the severity of the disease, with the highest dose (5 mg/kg) being the most efficient.
DISCUSSION
The finding that MTX treatment efficiently modulates some models for RA but not others indicates that MTX is not a general anti-inflammatory or joint protective agent but is more specifically directed to pathways operating more efficiently in only some forms of arthritis.
Clearly, MTX efficiently suppresses the classical CIA model even when given after the priming period and after the onset of arthritis. Because the treatment started after the onset of arthritis it did not affect the immune priming following immunisation or the earliest inflammatory events with synovial hyperplasia and infiltration of inflammatory cells. Thus, as expected, no effect was seen at the level of antibodies to CII, which is determined by activation of T cell dependent B cells during the immune priming process.
The joint targeted effector mechanism of the classical CIA model is probably quite complex involving T cell stimulation of synovial cells, T cell independent mesenchymal activation, and an arthritogenic effect by antibodies binding to cartilage. It is generally believed that, at least in the acute phase, the antibody mediated component dominates. [13] [14] [15] [16] [17] Consequently, serum from CII immunised mice and also CII-specific monoclonal antibodies transfer arthritis. 8 18-20 It was therefore surprising to find that MTX treatment had no effect on the CAIA model, indicating that MTX operates through another pathway not associated with arthritogenic antibodies in the CIA model. To test the possibility that MTX treatment is efficient in T cell dependent inflammatory models we used a model for multiple sclerosis induced with a peptide from MOG. 12 This is a T cell dependent model, which in contrast with CIA develops without the involvement of pathogenic antibodies. 21 22 In addition, it has been suggested that TNFa has no role or actually a protective role in MOG induced EAE. 23 Thus, TNFa has different roles in CIA and EAE. However, the effect of MTX was very similar in the CIA and EAE models underlining the fact that MTX operates on mechanisms shared between these two models.
To examine further the possibility that MTX influences T cell dependent pathways leading to arthritis we used the PIA model in DA rats. PIA is known to be both dependent on and mediated by T cells. 9 24 The disease can be transferred with CD4+abTCR+ T cells. 24 MTX turned out to be more potent but also more toxic in the rat, and at doses 10 times lower than those used in the mouse it was possible to suppress efficiently the development of established PIA. The mechanisms whereby T cells mediate arthritis are poorly known but they are likely to involve many types of synovial cells like macrophages and fibroblasts. These can be activated to secrete cytokines like TNFa or proteinases like matrix metalloproteinase-13 or differentiate into destructive cells like osteoclasts. [25] [26] [27] Both macrophages and fibroblasts can also be activated without the help of T cells, and the role of T cells in their activation is not clear.
To examine such downstream pathways without dissecting the precise mechanisms, we used an arthritis model induced with injection of activated fibroblasts into SCID mice. In this fibroblast mediated and T cell independent model, MTX treatment clearly had no effect, again indicating that the therapeutic effect is dependent on mechanisms in the joints that are T cell dependent. One earlier experiment described low dose MTX treatment of the CIA model, and the effects seen were similar to the results described here, although the treatment was started before onset. 28 A difference, however, was that in their experiments both antibodies and TNFa production by T cells were lowered. This effect is likely to be an effect by MTX on the immune priming in lymph nodes, a process not likely to be important for the results in our experimental set up in which immune priming had already occurred.
Our goal with these series of treatment experiments was not to identify the precise mechanisms of MTX, which are likely to be very complex, but rather to document the usefulness of various arthritis models. Clearly, the CIA and PIA models respond to MTX treatment, whereas the CAIA and fibroblast models do not. Thus, in the hypothetical case in which MTX was developed for human treatment today then MTX would have to be tested on animal models for it to comply with the FDA guidelines. Obviously in such a case MTX would only be seen as useful if the CIA or PIA models were used but not if the CAIA and SCID models were used.
However, this is only a short term treatment and, possibly, longer treatment, which is the standard treatment in humans, would have been more predictive. Obviously, treatment with MTX 1 day after onset of RA has not been performed and, additionally, it is difficult to predict the doses for treatment to be used as even mouse and rats differed dramatically in dose response.
Treatment mimicking the actual treatment in humans would have also required the use of chronic arthritis models, but this is not normally achievable easily for testing new drugs. Thus, anti-TNFa was not tested in such models, although it has later been shown to be efficient also in chronic arthritis. 29 In addition, RA is a complex and heterogeneous disease, and develops in discrete stages. It is important to develop treatments for different variants, and the effects on different models are therefore of value. As we have a limited knowledge of the variants of RA and because the in vivo mechanisms of newly developed drugs are unknown, it is difficult to predict which animal model should be used to verify the proof of principle of a drug. Therefore, it would be more beneficial to use a selected number of animal models with well characterised pathways and molecular mechanism. This will increase our knowledge about RA and shorten the time needed to obtain new beneficial treatments.
